Retreatment of Gefitinib in the Patients With Non-Small Cell Lung Cancer (NSCLC) Previously Responded to Gefitinib A Single Arm, Open Label, Phase II Study.

Trial Profile

Retreatment of Gefitinib in the Patients With Non-Small Cell Lung Cancer (NSCLC) Previously Responded to Gefitinib A Single Arm, Open Label, Phase II Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2013

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ReGaiN
  • Most Recent Events

    • 25 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Nov 2010 Planned End Date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 15 Nov 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top